Fulcrum Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
© -
All right. Welcome, everyone, to this session of the Crédit Suisse Healthcare Conference. I'm Judah Frommer, Smid-cap Biotech Analyst here at Crédit Suisse. And we're very excited to have Bryan Stuart, CEO of Fulcrum Therapeutics with us. Bryan, maybe we'll just jump in with an intro to the company, specifically some background on the FulcrumSeek platform that I think investors forget kind of drives the discovery process here.
Yes, absolutely. And thanks, everyone, for joining us. So Fulcrum was started about 6 or 7 years ago, really around the idea of identifying targets to modulate gene expression in order to come up with disease-modifying therapies for genetically defined rare diseases. So the whole idea is start with genetically defined rare disease, known root cause and look for a target that were either up or downregulate gene expression and be able to come up with a drug that is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
